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Abstract
Background/Aims: Cardiovascular disease is the most frequent cause of morbidity and 
mortality in autosomal dominant polycystic kidney disease (ADPKD) patients, often before 
the onset of renal failure, and the pathogenetic mechanism is not yet well elucidated. The 
aim of the study was to identify early and noninvasive markers of cardiovascular risk in 
young ADPKD patients, in the early stages of disease. Methods: A total of 26 patients with 
ADPKD and 24 control group, matched for age and sex, were enrolled, and we have assessed 
inflammatory indexes, mineral metabolism, metabolic state and markers of atherosclerosis 
and endothelial dysfunction (carotid intima media thickness (IMT), ankle brachial index 
(ABI), flow mediated dilation (FMD), renal resistive index (RRI), left ventricular mass index 
(LVMI)) and cardiopulmonary exercise testing (CPET), maximal O2 uptake (V’O2max), and 
O2 uptake at lactic acid threshold (V’O2@LT). Results: The ADPKD patients compared to 
control group, showed a significant higher mean value of LVMI, RRI, homocysteine (Hcy), 
Homeostasis Model Assessment-insulin resistance (HOMA-IR), serum uric acid (SUA), Cardiac-
troponinT (cTnT) and intact parathyroid hormone (iPTH) (p<0.001, p<0.001, p<0.001, p<0.001, 
p<0.001, p=0.007, p=0.019; respectively), and a lower value of FMD and 25-hydroxyvitaminD 
(25-OH-VitD) (p<0.001, p<0.001) with reduced parameters of exercise tolerance, as V’O2max, 
V’O2max/Kg and V’O2max (% predicted) (p<0.001, p<0.001, p=0.018; respectively), and 
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metabolic response indexes (V’O2@LT, V’O2 @LT%, V’O2@LT/Kg,) (p<0.001, p=0.14, p<0.001; 
respectively). Moreover, inflammatory indexes were significantly higher in ADPKD patients, 
and we found a positive correlation between HOMA-IR and C-reactive protein (CRP) (r=0.507, 
p=0.008), and a negative correlation between HOMA-IR and 25-OH-VitD (r=-0.585, p=0.002). 
Conclusion: In our study, ADPKD patients, in the early stages of disease, showed a greater 
insulin resistance, endothelial dysfunction, inflammation and mineral metabolism disorders, 
respect to control group. Moreover, these patients presented reduced tolerance to stress, and 
decreased anaerobic threshold to CPET. Our results indicate a major and early cardiovascular 
risk in ADPKD patients. Therefore early and noninvasive markers of cardiovascular risk and 
CPET should be carried out, in ADPKD patients, in the early stages of disease, despite the cost 
implication.
IntroductionAutosomal dominant polycystic kidney disease (ADPKD) is the most common inherited 
renal disorder, characterized by progressive fluid-filled cyst development, and growth that 
lead to end stage renal disease (ESRD) in 50% of patients, by the age of 50-60 years [1-3]. The 
estimated prevalence is between 1:400 and 1:1000 live births [4]. About 8–10% of patients on 
renal replacement therapy (RRT) are affected by ADPKD [5-7]. Mutations in two genes, PKD1 
(localized on chromosome region 16p13.3 and encoding polycystin 1 [PC1]; ∼85% of cases) 
and PKD2 (localized on chromosome region 4q21 and encoding polycystyn 2 [PC2]; ∼15% 
of cases) [8-10], cause the disease. Mutations in PC1 and PC2, transmembranes glicoproteins 
that are colocalized to the primary cilium of the kidney tubular epithelial cells, cause lower intracellular levels of calcium and increased intracellular cyclic adenosine monophosphate, 
with aberrant cell proliferation and fluid secretion into cysts [11-13]. ADPKD is a systemic 
disease, that may involve different organs, showing a high phenotypic variability [14-15], 
and cardiovascular complications are the major cause of morbidity and mortality, with a 
cardiac-related death that is estimated to be 1.6- to 3.2-fold higher in these patients than in 
the general population [16-17]. Currently, there are no prognostic tools to identify ADPKD 
patients with high cardiovascular risk.
Materials and Methods
The study was approved by the Local Clinical Research Ethics Committee, with protocol number 
3169/15. The study conforms to the principles outlined in the Declaration of Helsinki, and we obtained a 
written consent by each patient enrolled.
Study design and subjects
We performed an observational, cross-sectional study on 50 patients, 26 ADPKD patients and 24 
control group matched for age and sex, at the University Hospital “Policlinico Umberto I” of Rome, Sapienza 
University of Rome, Italy. Patients were enrolled from July 2015 to April 2016.
Patients
A total of 26 patients affected by ADPKD (6 male; 20 female), and 24 control group (8 male; 16 female), 
were matched for age and sex. 21 ADPKD patients and 18 control group patients were hypertensive. The 
presence of secondary hypertension had previously ruled out. Both groups had good blood pressure control 
and antihypertensive therapies were continued in all patients included in the study (Table 1). Two patients 
of ADPKD group were smoker, and one patient of control group was a mildly smoker up to 8 years before.
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Inclusion criteria
Patients aged >18 years with ADPKD
ADPKD was defined according to the Pei’s 
criteria [18]. Estimated Glomerular Filtration 
Rate (eGFR) ≥ 80 ml/min
The eGFR was calculated with the abbreviated 
Chronic kidney disease-epidemiology formula 
(CKD-EPI), as defined by Levey et al [19].
Exclusion criteriaWe recorded the cardiovascular history and excluded patients affected by heart failure, neoplastic diseases, chronic liver disease, 
chronic obstructive airway disease, congenital heart disease, cerebrovascular disease, carotid artery 
stenosis, and acute coronary syndrome three months before of the study.  We excluded also patients with 
diabetes, urinary abnormalities, suggestive of concomitant glomerular disease and urinary tract infection. 
Patients who refused to give consent and patients with missing data.
All patients performed the morpho-functional Magnetic Resonance (MR) without contrast medium, to 
exclude the presence of cerebral aneurysms, exclusion criterion of this study.
Laboratory measurements
Blood was sampled the morning after overnight fasting of at least 12 h, for laboratory assessment. In 
all patients, the levels of fasting plasma glucose (mg/dL), insulin (µU/mL), total serum cholesterol (mg/dL), 
triglycerides (mg/dL), high-density lipoprotein (HDL) (mg/dL), creatinine (mg/dL), serum nitrogen (mg/
dL), serum uric acid (SUA) (mg/dL), fibrinogen (mg/dL), calcium (mg/dL), phosphorus (mg/dL), serum 
electrolytes (mEq/L), C-reactive protein (CRP) (μg/L), homocysteine (Hcy) (µmol/L), hemoglobin (Hb) (g/
dL), were measured using standard automated techniques. The total white blood cell count (WBC) and the 
neutrophil, lymphocyte and platelet counts were recorded. The neutrophil-lymphocyte ratio (NLR), was 
calculated by dividing the absolute neutrophil count by the absolute lymphocyte count (NLR < 2.8, was 
defined as low in our study). LDL-cholesterol was calculated using the Friedewald equation: LDL (mg/dL) 
= total cholesterol−HDL− (triglycerides/5). Parathyroid Hormone was measured using a two-site assay that 
measures “intact” hormone (iPTH) (pg/mL) and 25-hydroxyvitaminD (25-OH-VitD) (ng/mL) was measured 
by radioimmunoassay. Cardiac troponin T (cTnT) (ng/mL) were measured using automated analyzer 
Elecsys ®2010 (Roche Elecsys 2010 chemistry analyzer, Cobas Integra 400 Plus Analyzer, Geislingen, 
Germany). Serum albumin (g/dL) was determined by bromcresol purple method. Insulin resistance was 
assessed using the homeostasis model assessment (HOMA-IR), originally described by Mathew et al [20]. 
Microalbuminuria 24 h (30-300 mg/24h) were carried out.
Anthropometric assessments
Body weight was determined to the nearest 0.1 kg using a calibrated digital scale. Body mass index was 
calculated from a person’s weight and height [weight (kg)/height2 (m2)].
Blood pressure measurements
Blood pressure (BP) measurements were made in the dominant arm, after 10 minutes of rest in the sitting position, using a standard automatic sphygmomanometer and cuffs adapted to the arm circumference 
[21]. The mean of the three measurements was recorded for statistical analyses.
The systolic and diastolic BP levels were taken as the points of appearance and disappearance of 
Korotkoff sounds, respectively. Hypertension was defined as systolic BP ≥140 mmHg or diastolic BP ≥ 90 
mmHg on repeated measurements. We have determined Ankle Brachial Index (ABI), the measurement of 
the ratio of the systolic blood pressures in the ankle and in the arm (normal values 0.9-1) [22].
Echocardiography
All patients underwent transthoracic echocardiography with a commercially available cardiovascular 
Table 1. Patient’ s characteristics. Data are show as 
mean ± standard deviation. Abbreviations: SBP, diurnal 
systolic blood pressure; DBP, diurnal diastolic blood 
pressure; ADPKD, autosomal dominant polycystic 
kidney disease; yrs, years; num, number  
 ADPKD (n:26) Control Group (n:24) p value SBP (mmHg)  122.6±15.2 120.8±9.9 n.s. DBP (mmHg) 78.2±9.7 73.1±10.8 n.s. duration of hypertension (yrs) 8.2 ± 4.1  6.7 ± 3.3 n.s. Ace inhibitors (num) 8 6 n.s. ARBs (num) 4 3 n.s. Ca-antagonists (num) 7 8 n.s. 
β-blockers (num) 2 1 n.s.                                
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ultrasound system (Vivid E9, GE, Horten, Norway). Measurements of cardiac chambers were made according 
to established criteria [23-24]. LV ejection fraction by modified biplane Simpson method and mass index 
were estimated. Peak early (E) and late (A) diastolic velocities, deceleration time, left ventricular isovolumic 
relaxation time, and myocardial performance index were obtained using standard Doppler practices. 
Standard parasternal, apical, and subcostal views were used.
Common carotid intima-media thickness assessment (IMT)
Right (R) and left (L) carotid ultrasound was blindly performed by an experienced sonographer, who 
was unaware of the characteristics of the patients under examination. Participants were studied with the 
high-resolution B-mode ultrasound machine Toshiba Aplio XV (Toshiba AplioxV, Toshiba American Medical 
Systems, Inc., Tustin, CA, USA) equipped with a 5- to 12-MHz linear transducer with a 0.01-mm resolution, 
following a standardized vascular protocol [25]. IMT was measured at three points on the far walls of both left and right distal common carotid arteries, carotid bulb, and the proximal portion of the internal carotid 
arteries. The mean IMT was calculated as the average IMT on both sides. The value of IMT was considered 
normal when between 0.55 and 0, 9 mm [26].
Flow-mediated dilation brachial artery (FMD)
According to the method described by Celermajer and others [27], the endothelium-dependent 
vasodilation (FMD) of the brachial artery was assessed using a high-resolution B-mode ultrasound machine 
Toshiba Aplio XV (Toshiba AplioxV, Toshiba American Medical Systems, Inc., Tustin, CA, USA), equipped 
with a 5- to 12 MHz linear transducer with a 0.01-mm resolution, by the same blinded experienced 
ultrasonographer, following a standardized vascular protocol [28]. Flow-mediated vasodilatation was 
typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter. FMD: 
(diameter post-hyperemia-basal diameter/basal diameter) x 100. The values of FMD were considered 
normal if they were greater than 10%.
Renal Resistive index (RRI)
Participants were studied with the high-resolution B-mode ultrasound machine Toshiba Aplio XV 
(Toshiba AplioxV, Toshiba American Medical Systems, Inc., Tustin, CA, USA) equipped with a 3-3.5 MHz 
convex transducer. All measurements were made by a single, blinded, experienced ultrasonographer. Renal 
resistive index (RRI) values were determined with the mean of three separate measurements in the renal superior pole, interpolar regional and inferior pole on the level of the interlobular, interlobar or arcuate 
arteries in both kidneys. We used an anterior and an oblique approach, to detect the renal arteries and intra-
parenchymal vessels, and we used a posterior approach with adjustment of direction if the cystic lesions 
were too large and did not permit a clear view. Three to five reproducible and consecutive waveforms with 
similar aspect from each kidney were obtained. These measurements were used to calculate the average 
RI value for each kidney, and then the average RI value for each patient was calculated as the mean of the 
RI in the left and right kidney [29]. We determined the peak systolic velocity and end-diastolic velocity 
(centimeters/second) to calculate the RRI as = [1-(end-diastolic velocity ÷ maximal systolic velocity)] x 100 
[30-31]. The intra-reader correlation coefficient for RRI was 0.97, whereas the inter-reader was 0.92.
Magnetic Resonance Imaging (MRI)
All patients underwent MR examinations at 3T magnet to assess the presence of intracranial arterial 
aneurysms and Total kidney volume. Imaging was performed with a 3.0-T MR unit (Verio; Siemens, Erlangen, 
Germany).
Respiratory function testing (Spirometry)
Spirometries were executed with the subjects in sitting position, wearing a nose clip according to 
the international guidelines [32-33]. Before testing each subject, the spirometer was calibrated using a 
certified 3-L syringe. A laboratory spirometer and Quark spirometry software (Quark PFT Suite Version 
9.1a, COSMED, Pavona, Italy) were used to measure forced expiratory volume in one second (FEV
1
) and 
forced vital capacity (FVC).
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Cardiopulmonary exercise testing (CPET)
All subjects performed an incremental exercise test up to peak work capacity on an electronically 
braked cycle ergometer (COSMED, Pavona, Italy), using the Quark b2 system (Version 8.1a, COSMED, Pavona, 
Italy) according to guidelines [34]. All participants were continuously monitored by means of a 12-lead 
electrocardiograph. Blood pressure was measured every minute using a sphygmomanometer. Percentage of 
arterial oxygen saturation was continuously measured using a pulse oximeter. Oxygen uptake (V’O2), carbon 
dioxide production (V’CO2) and minute ventilation (V’E) were detected. CPET consisted of a steady-state 
resting period, then one minute of warm-up without load, followed by a stepwise protocol in which the 
work rate was increased in 1-minute intervals by increments of 10 Watt.The exercise test was considered 
maximal for a value of respiratory exchange ratio (RER) > 1.05. The test was continued until the point of 
symptom limitation (peak exercise). Subjects were asked to score their sense of breathlessness and muscle 
fatigue throughout the exercise and at peak exercise using Borg scale [35]. The Lactic Threshold (LT) was 
detected individually using the V-slope method [36]. Workload (W), LT, maximal oxygen consumption 
(V’O2max) and HR peak values, BP for each subject were compared with those obtained in a group of healthy 
subjects matched for age, height, weight and gender.
Statistical analysis
Data management and analysis were performed using IBM® SPSS® Statistics 18.0 for Windows® 
software (IBM Corporation, New Orchard Road Armonk, New York, United States). The normality of 
variables was tested using the Shapiro-Wilk method for normal distributions. All continuous variables were 
expressed as mean ± standard deviation, categorical variables were expressed as number (percentage). 
The comparison of the data of patients, for all quantitative variables considered was performed using 
non-parametric Wilcoxon test and Student’s t test. For comparing proportions was applied Chi-Square 
Test. Student’s t-test or-Mann-Whitney U-test were performed to determine differences between groups. 
Binomial Test or Chi-square test was used for 
comparison of categorical data. Pearson’s or 
Spearman’s Correlation was used to determine in bivariate correlation the relationship and the 
strength of association between the variables. A 
probability value of p < 0.05 was considered to be 
statistically significant.
Results
The study included 26 consecutive 
patients affected by ADPKD (6 male; 20 
female), with a mean age of 31.7 ± 9.1 years, and 24 control group (8 male; 16 
female), with a mean age of 27.8 ± 4.5 
years. Population characteristics are 
shown in Table 2. There were no significant 
differences between the two groups 
regarding age, BMI, BP, eGFR (ml/min), 
sodium (mEq/L), potassium (mEq/L), 
calcium (mg/dL), phosphorus (mg/dL), 
glycemia (mg/dL), serum nitrogen (mg/
dL), and Hb (g/dL), while we reported 
a significant difference in SUA (mg/dL), 
Hcy (µmol/L) and HOMA-IR, (p<0.001, 
p<0.001, p<0.001; respectively) (Table 2). 
Moreover, we found higher iPTH (pg/mL) in 
Table 2. Patient’ s characteristics. Data are shown 
as mean ± standard deviation. Abbrevitions: BMI, 
Body Mass Index; SBP, Systolic Blood Pressure; 
DBP, Diastolic Blood Pressure; eGFR, estimated 
Glomerular Filtration Rate; Hb, Hemoglobin; 
NLR, Neutrophil / Lymphocyte ratio; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; 
iPTH, intact Parathormone; 25-OH-VitD, 
25-hydroxyvitaminD; Hcy, homocysteine; cTnT, 
Cardiac troponin T; CRP, C-reactive proteinVariable ADPKD Control Group p value Age 31.7±9.1 27.8±4.5 0.067 BMI 22.9±2.8 22.6±2.0 0.665 SBP (mmHg) 122.6±15.2 120.8±9.9 0.632 DBP(mmHg) 78.2±9.7 73.1±10.8 0.090 eGFR (mL/min) 98.9±19.9 107.2±9.1 0.066 Creatinine (mg/dL) 0,81± 0,15  0.77±0.13 0.320 hATKV cm3 820.06±812.82   Urea (mg/dL) 37.6±10.1 33.4±5.0 0.075 Uric Acid (mg/dL) 5.1±1.1 3.542±0.116 <0.001 Sodium (mEq/L) 140.4±1.8 140.2±2.3 0.654 Potassium (mEq/L) 4.3±0.3 4.1±0.3 0.073 Clalcium (mEq/L) 9.4±0.4 9.2±0.2 0.068 Posphorus (mEq/L) 3.5±0.5 3.3±0.5 0.114 Hb (g/dL) 13.2±1.4 13.0±1.2 0.665 Neutrofil (x103/mL) 3990.7±1305.1 4445.8±1497.4 0.257 Lymphocyte (103/mL) 1569.4±701.6 2520.2±516.0 <0.001 NLR 2.72±1.42 1.76±0.55 0.003 HOMA-IR 2.51±1.50 1.35±0.47 <0.001 Glycemia (mg/dL) 86.4±8.2 83.5±7.6 0.201 Total Colesterol (mg/dL) 176.3±32.2 156.3±28.5 0.025 HDL (mg/dL) 59.2±16.9 64.9±14.4 0.212 LDL (mg/dL) 98.8±8.2 76.0±9.4 <0.001 Tryglicerides (mg/dL) 85.7±34.0 73.3±28.2 0.170 iPTH (pg/mL) 48.4±23.2 35.9±10.6 0.019 (25-OH-VitD) (ng/mL) 14.0±9.5 28.3±6.2 <0.001 Fibrinogen (mg/dL) 312.0±79.4 267.9±44.6 0.020 Albumin (g/dL) 4.343±0.377 4.805±0.435 0.002 Hcy (µmol/L) 16.628±7.724 8.917±1.984 <0.001 CTnT(ng/mL) 0.014±0.019 0.003±0.004 0.007 
CRP (μg/L) 7007.6±6950.1 1206.8±1122.1 0.002                     
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ADPKD patients (mg/dL) respect 
to control group, although within 
normal values, (p=0.019)(Table 
2) and lower 25-OH-VitD (ng/mL) 
(p<0.001) (Table 2). Inflammatory 
indexes, as NLR, CRP (µg/L) and 
fibrinogen, were significantly higher in ADPKD patients respect 
to control group (p=0.003, 
p=0.002, p=0.020; respectively)
(Table 2). Total Cholesterol (mg/
dL) and LDL (mg/dL) were 
significantly different between the 
two groups (p=0.025, p<0.001; 
respectively), while HDL (mg/
dL) and triglycerides (mg/dL) did 
not show significant differences 
(p=0.212, p=0.170; respectively) 
(Table 2). Also albumin (g/
dL) value, was significantly 
different between the two groups, 
although within normal values 
(p=0.002). Furthermore, we found 
significantly higher mean values of 
LVMI (g/m²), RRI and cTnT (ng/
mL) (p<0.001, p<0.001, p=0.007; 
respectively), and lower FMD 
value (p<0.001) (Table 2, Table 3), in ADPKD patients versus control 
group, while we did not found a 
significant difference in IMT and 
ABI values (p=0.932, p=0.495; 
respectively), between the two 
groups (Table 3). In ADPKD patients, the study correlation 
showed a positive correlation 
between HOMA-IR and CRP 
(r=0.507, p=0.008) (Fig. 1), and a negative correlation between HOMA-IR and 25-OH-VitD 
(r=-0.585, p=0.002) (Fig. 2). Also, we found significantly reduced parameters of exercise tolerance, as V’O2max, V’O2max/Kg and V’O2max (% predicted) (p<0.001, p<0.001, p=0.018; respectively) and metabolic response indexes (V’O2@LT, V’O2@LT%, V’O2@LT/Kg,) (p<0.001, 
p=0.14, p<0.001; respectively) in ADPKD patients compared to control group (Table 4). 
Conversely, we found significantly increased the ventilatory equivalent for CO2, V’E/V’CO2@
LT (p<0.001). HR peak was reduced in ADPKD patients (p<0.001), while no statistically 
significant difference was found in HR rest (p=0.351). The remaining parameters of the 
CPET did not show statistically significant differences between the two groups.
Discussion
The most important finding of our study is the early appearance of inflammatory indexes, 
endothelial dysfunction, atherosclerotic and metabolic markers associated with a reduction of parameters of exercise tolerance and metabolic response indexes in ADPKD patients 
Fig. 1. Linear regression plot. Correlation between HOMA-
IR and CRP (μg/L) in ADPKD patients, r=0.507, p=0.008. 
Abbreviations: HOMA-IR, homeostasis model assessment of 
insulin resistance; ADPKD, autosomal dominant polycystic 
kidney disease; CRP, C reactive protein.
Table 3. Instrumental parameters of the study participants. 
Data are shown as mean±standard deviation. Abbreviations: 
ADPKD autosomal dominant polycystic kidney disease; FMD, 
flow mediated dilation; cIMT, carotid intima media thickness; 
LVMI, left ventricular mass index; RRI, renal resistive index; 
ABI, ankle brachial indexVariable ADPKD Control Group p value FMD 11,23±5,66 27,46±5,29 <0,001 cIMT 0,65±0,13 0,64±0,12 0.779 LVMI 125,04±24,12 83,80±11,43 <0,001 RRI 0,64±0,057 0,55±0,03 <0,001 ABI 1.01 ± 0.06 1.00 ± 0.04 0.495                                  
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respect to control group. ADPKD is characterized by several cardiovascular 
complications, which represent the main cause of death of this disease 
[11]. The onset of cardiac manifestations, such as hypertension, left ventricular hypertrophy 
(LVH), cardiac valvular abnormalities and pericardial effusions, may precede the development of 
renal failure [9]. Despite the pathogenetic mechanisms 
are not well understood, endothelial dysfunction, 
inflammation, and insulin resistance, are the most commonly encountered risk factors in the pathogenesis of cardiovascular disease in ADPKD patients, also in the 
early stages of disease [37]. 
Leier et al. [11] hypothesized a generalized connective 
tissue dysfunction, with a 
deficiency or absence of 
type III collagen. Several lines of evidence, suggest 
a hyperactivation of renin-
angiotensin-aldosterone 
system (RAAS), with ectopic production of renin, angiotensinogen , 
angiotensin-converting enzyme and angiotensin 
II by cystic epithelium [2, 
12]. Angiotensin II seems to represent the main stimulus for the production of aldosterone, and the presence of hyperaldosteronism in ADPKD, could contribute to 
the development of insulin resistance and endothelial dysfunction, with impaired nitric 
oxide-related vasorelaxation, and progression of cardiorenal disease [15]. Recently, 
some authors showed an essential role of the cilia in proper development of the vascular 
system [16]. Insufficient expression of PC1 or PC2 could be associated with functional or structural abnormalities of the vascular system, determining a reduced release of nitric 
oxide with altered endothelial response to shear stress and reduced vasodilation [17]. Our 
data confirm that ADPKD patients, with preserved renal function, show a significant higher 
LVMI (Table 3), which is likely multifactorial, and may be influenced by vitamin D deficiency, 
hyperparathyroidism and insulin resistance [38]. In this study, we showed higher mean value 
of iPTH, although remaining within the normal range, and lower 25-OH-VitD levels in ADPKD 
Fig. 2. Linear regression plot. Correlation between HOMA-IR 
and 25-OH-VitD (ng/mL) in ADPKD patients, r=-0.585, p=0.002. 
Abbreviations: HOMA-IR, homeostasis model assessment of insulin 
resistance; ADPKD, autosomal dominant polycystic kidney disease; 
25-OH-VitD, 25-Hydroxyvitamin D.
Table 4. Instrumental parameters of the study participants. Data 
are shown as mean±standard deviation. Abbreviations: ADPKD, 
autosomal dominant polycystic kidney disease; V’O2max, maximum 
oxygen uptake; V’O2max (% predicted), maximum oxygen uptake percent 
of predicted; V’O2max/Kg, maximum oxygen uptake ratio for kilogram; 
V’O2@LT, oxygen uptake at lactic threshold; V’O2@LT (% predicted), 
oxygen uptake at lactic threshold percent of predicted; V’O2@LT/Kg, 
oxygen uptake at lactic threshold ratio for kilogram; V’E/V’CO2@LT, 
ventilatory equivalent ratio for carbon dioxide at lactic threshold; HR, heart rate  Variable ADPKD Control Group p value V'O2max (ml/min) 1646,00±395,69 2430,20±503,08 <0,001 V'O2max (% predicted) 79,74±13,82 90,09±16,21 0,018 V'O2max/Kg (ml/min/Kg) 25,04±3,36 33,62±5,03 <0,001 V'O2@LT (ml/min) 906,67±163,95 1299,79±415,46 <0,001 V'O2@LT (% predicted) 40,42±8,58 47,68±11,52 0,014 V'O2@LT/Kg (ml/min/Kg) 13,07± 3,36 17,87±4,68 <0,001 V'E/V'CO2@LT 28,24±2,94 24,61±3,37 <0,001 HR rest (bpm) 80,36±15,34 84,04±11,86 0,350 HR peak (bpm) 155,04±18,95 172,79±11,13 <0,001 
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patients, compared to control group. Although the involvement of Vitamin D in ADPKD is 
not fully elucidated, it is known that it is responsible of pleiotropic effects, by binding to 
the vitamin D receptor (VDRs), in non-classical targets, including cardiovascular, immune-
endocrine, and nervous systems [26]. Moreover, Vitamin D deficiency reduces intestinal 
calcium absorption by more than 50%, and determines an increase in the levels of iPTH. An 
increased iPTH level may be associated with left ventricular and vascular medial smooth 
muscle hypertrophy. Vitamin D deficiency, and/or increased iPTH, could, at least partially, explain hypertrophy of the left ventricle and proliferation of vascular smooth muscle cells, 
promoting atherosclerosis and endothelial dysfunction [39-40]. Vitamin D is also involved in glycemic control, insulin secretion, and sensitivity, partially explaining the negative 
correlation found in our study, between 25-OH-VitD and HOMA-IR (Fig. 2). Currently, the link 
between polycystin function and insulin resistance, in ADPKD patients with preserved renal 
function, is still poorly known [41], even if recently Mao et al. [42] showed that polycystin 
proteins could regulate insulin secretion, being expressed in pancreatic islet beta cells. 
Other significant metabolic alterations were observed in ADPKD patients in our study, like 
higher Hcy and SUA respect to control group. Both of them are independent risk factors 
for atherosclerosis and cardiovascular disease [26], and could influence the endothelial dysfunction, through the generation of oxidative stress, promoting the development of 
inflammation and atherosclerosis [43]. Moreover in ADPKD patients, SUA may be considered 
an independent factor for renal progression [44], and associated with earlier onset of larger 
kidney volume, hypertension, and increased hazard for ESRD [45-46]. Chronic inflammation 
has been shown to be an independent predictor of cardiovascular mortality in ADPKD patients 
[47]. In our study, inflammatory markers as CRP, fibrinogen levels and NLR were significantly 
higher in patients with ADPKD compared to control group, in the early stages of disease. 
Moreover, CRP showed a positive correlation with HOMA-IR (Fig. 1). In recent years, NLR 
was introduced as a potential marker to determine inflammation in cardiac and noncardiac 
diseases [48]. The early metabolic and inflammatory changes that we showed, could explain 
the lower FMD value, and the higher mean values of LVMI and RRI, which are early markers 
of endothelial and cardiac dysfunction, in ADPKD patients respect to control group [49-51]. 
Conversely, in our study, we have not revealed a significant difference in IMT and ABI, indexes of subclinical atherosclerosis, perhaps because ADPKD patients are still in the early stages of 
disease. Indeed, endothelial dysfunction is an early and potentially reversible manifestation 
of atherosclerosis, with multifactorial etiology [52-54], and it develops in ADPKD patients, 
preceding the renal failure [55-56]. Atherosclerosis has been considered to play a key role 
in the early phases of cardiovascular disease found in ADPKD [57-59]. Cardiopulmonary 
exercise testing is considered the gold-standard for assessment of cardiorespiratory fitness. 
Measurement of maximum oxygen uptake (V’O2max) is the most important parameter used 
in the evaluation of exercise tolerance. Cardiopulmonary exercise testing measures the integrated physiological responses to exercise of respiratory, cardiovascular, and skeletal 
muscle systems [60]. In our study, we found a statistically significant reduction of parameters of exercise tolerance as V’O2max, V’O2max/Kg and V’O2max (% predicted), and metabolic response indexes (V’O2 @LT, V’O2 @LT %, V’O2 @LT/Kg,) (Table 4), in ADPKD patients compared to 
control group. The ventilatory equivalent for CO2 at lactate threshold (V’E/V’CO2@LT) was 
significantly increased in ADPKD patients (Table 4). Impaired physical capacity in young 
patients with ADPKD could be explained by underlying endothelial dysfunction, which could 
depend on inadequate response of nitric oxide, asymmetric dimethylarginine, and BP to 
acute exercise [36, 61]. Several studies have identified V’E/V’CO2, anaerobic threshold, and 
V’O2max as prognostic factors in cardiovascular diseases [62-63]. We found, also, a significant 
increase of cTnT in ADPKD patients, a sensitive and specific marker of ischemic myocardial 
damage, renally cleared, and widely used as a predictor of cardiovascular events [53]. Our 
results indicate an increase of the indexes of inflammation and endothelial dysfunction, with 
reduced tolerance to stress and decreased anaerobic threshold to CPET, in young ADPKD 
patients, with preserved renal function, in the early stages of disease, compared to control 
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group. Moreover CPET could allow an early assessment of maximum oxygen uptake and 
anaerobic threshold, and it could be used in the follow up to assess response to possible therapeutic strategies, as vitamin D supplement, hyperuricemia and hyperhomocysteinemia correction, diet and regular physical activity, that could improve the exercise tolerance and 
metabolic state [64].
Limitation of the study
This study was conducted in relatively small cohort of ADPKD patients; therefore should 
be considered as hypothesis generating data, which need to be confirmed by further clinical 
studies with a larger number of patients.  Moreover, it is based on associations with surrogate 
end points, indeed it demonstrated an ‘association’, rather than a ‘causality’ relationship; the 
generated hypothesis thus needs further prospective follow-up studies with a larger number 
of patients and stronger end points to show causality.
Conclusion
Cardiovascular manifestations are common in ADPKD, and starts very early during the 
course of the disease. There are currently no prognostic tools to identify ADPKD patients 
with high cardiovascular risk [65]. The early and noninvasive evaluation of inflammatory 
indexes, endothelial dysfunction, atherosclerotic markers and HOMA-IR, in addiction to 
mineral metabolism indexes and cTnT may be necessary to improve the cardiovascular 
prognosis of affected patients, especially in the early stages of disease, when renal function 
is still preserved, despite the cost implication. Large clinical trials are needed to establish cardiovascular risk in ADPKD patients and further studies are necessary to determine if the 
progression of ADPKD is modified by treatment risk factors, such as vitamin D deficit, insulin 
resistance, hyperuricemia and hyperhomocysteinemia [66].
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